Transversus Abdominis Plane (TAP) Versus Local Anesthetic for Lap Appendectomies

Model scores of the 29,894 trials active now.

Model score 33% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (331 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: doubleanalgesiaproceduresphysicalrandomized
  Phrases that lowered it: patientsstatuswill receivehave receivedii
• Sponsor's past termination rate: 26.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 15 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.3% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 88.6% (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 3940 (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 519 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ultrasound Guided Transversus Abdominis Plane Block in Pediatric Surgery NCT02723487 · started 2016 · scored riskier than 23% of active trials completed
• Transversus Abdominis Plane Versus Caudal Block for Pediatrics NCT02398123 · started 2015 · scored riskier than 22% of active trials completed
• TAP Block for Postoperative Pain Control NCT02652156 · started 2015 · scored riskier than 16% of active trials terminated
• Combined Ketorolac Bupivacaine Versus Bupivacaine Alone for TAP Block in Children Undergoing Lower Abdominal Surgeries NCT06267820 · started 2023 · scored riskier than 7% of active trials completed
• Dexmedetomidine Versus Fentanyl Added to Levobupivacaine for Transversus Abdominis Plane (TAP) Block NCT03778671 · started 2019 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.